



Modus Therapeutics announces two new U.S. patents for its candidate drug sevuparin

STOCKHOLM – November 7, 2016. Modus Therapeutics AB, a clinical-stage drug development company focused on innovative treatments for patients with sickle-cell disease, today announced that it has been granted two patents in the U.S. covering its proprietary compound sevuparin. More specifically the two patents have been granted claims for the substance sevuparin *per se* and a manufacturing method for producing sevuparin (U.S. Patent no. 9,480,701) as well as its use in e.g. Sickle Cell Disease (U.S. Patent No. 9.480,702).

The two US patents granted by the United States Patent and Trademark Office (USPTO) will provide key intellectual property protection in the US for Modus' candidate drug sevuparin until at least December 2032, with the possibility for up to five years' extension after a market approval. Corresponding patent applications have been submitted in a broad range of other territories including Europe, Asia and Latin America.

Modus is currently enrolling SCD patients into a multi-centre, international, randomised Phase II study in Europe and the Middle East. This proof-of-concept study is designed to demonstrate reduced time to resolution of Vaso-Occlusive Crises (VOC) in SCD patients.

Christina Herder, CEO of Modus Therapeutics, said: "The grant of these two U.S. patents is a major milestone for Modus as they provide important IP protection for sevuparin and its use for SCD. The US, with 100,000 SCD patients, represents a significant opportunity for sevuparin."

For further information: Christina Herder, CEO, Tel: + 46 70 374 71 56,
christina.herder@modustx.com

David Dible or Pip Batty, Citigate Dewe Rogerson, Tel: +44 207 282 2049/1022,
modustx@citigatedr.co.uk

About Modus Therapeutics AB

Modus Therapeutics is a clinical-stage drug development company developing new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in rare diseases with large unmet medical need. The Company's most advanced candidate, sevuparin, is currently being evaluated in a Phase II clinical trial in sickle cell disease (SCD). Repeated painful crises in SCD, so called vaso-occlusive crises ("VOC"), leads to loss of vital organ function and often significantly reduced life span.

Modus Therapeutics is based in Stockholm. The Company's major shareholders are KDev Investments AB (an investment fund jointly owned by Karolinska Development AB and Rosetta Capital), Östersjöstiftelsen (The Foundation for Baltic and East European Studies), and Praktikerinvest PE AB.

For more information, please visit www.modustx.com.

About sevuparin

Sevuparin is an innovative, disease-modifying proprietary polysaccharide drug, which has the potential to restore blood flow and prevent further microvascular obstructions in SCD patients via a multimodal, anti-adhesive mechanism. The microvascular obstructions cause the severe pain during VOCs and the high morbidity through organ damage as well the risk of premature death.

Modus Therapeutics has received Orphan Drug Designation for sevuparin for use in SCD in the US and EU.

About Sickle Cell Disease

Sickle cell disease (SCD) is a painful, inherited blood disorder affecting millions of people around the globe and the most common inherited blood disorder in the US affecting between 90,000-100,000 subjects, with medical care costs amounting to more than \$1 billion. In Europe it is estimated that there are 35,000-40,000 SCD patients, and this number is higher in the Middle East and North Africa regions, with over 850,000 SCD patients.

There is currently no pharmaceutical product available that targets the underlying cause of VOCs that affect SCD patients. Current therapies are predominantly strong intravenous pain medications and SCD patients often have to be hospitalized in order to be treated.